Alpha-Lipoic Acid
α-Lipoic Acid · Thioctic Acid · The Universal Antioxidant
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The evidence sits at mixed-to-moderate, and the honest number for diabetic peripheral neuropathy is a 3 rather than a 4. The strongest signal comes from short-term intravenous use. Ziegler's 2004 meta-analysis of four industry-linked trials (ALADIN I, ALADIN III, SYDNEY, NATHAN II, roughly 1,258 patients) found that 600 mg/day IV over three weeks reduced the Total Symptom Score by about 24 percent versus placebo, with responder rates of 53 percent against 37 percent. Oral evidence is weaker. The five-week SYDNEY 2 dose-ranging trial (Ziegler 2006, 181 patients) showed symptom improvement with 600 mg once daily as the best risk-benefit dose, but the four-year NATHAN 1 trial (Ziegler 2011, 460 patients on 600 mg oral) missed its primary composite endpoint (P = 0.105), showing no durable slowing of nerve impairment. Most tellingly, the 2024 Cochrane review (Baicus) concluded that oral ALA probably has little or no clinically meaningful effect on neuropathy symptoms at six months on moderate-certainty evidence, and flagged high attrition-bias risk across trials. Symptomatic short-term relief is real and defensible; disease-modifying benefit is not established. Weight-loss and metabolic claims are modest at best.
- FDA
- Legal supplement (US); Rx Thioctacid (Germany, diabetic neuropathy)
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Generally well tolerated, but can lower blood sugar (hypoglycemia risk with diabetes drugs) and carries a rare, documented link to insulin autoimmune syndrome, most often in people carrying HLA-DRB1*04:06.
Alpha-lipoic acid is a naturally occurring compound the body makes in small amounts and uses as a cofactor in mitochondrial energy metabolism. It is often marketed as the universal antioxidant because it is soluble in both water and fat and can help regenerate other antioxidants such as glutathione, vitamin C and vitamin E. Its best-supported use is symptomatic relief of diabetic peripheral neuropathy, and Germany has long approved a prescription form (Thioctacid) for that indication. The short-term intravenous data are the most convincing; oral and long-term results are weaker, and a 2024 Cochrane review found probably little or no clinically meaningful benefit at six months. Weight-loss and other metabolic claims are real but small.
A German prescription drug for diabetic neuropathy, a US supplement for metabolic health.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Alpha-lipoic acid is a small disulfide compound (1,2-dithiolane-3-pentanoic acid) that occupies a unique chemical position among antioxidants, soluble in both water and fat. This dual solubility allows it to operate in essentially every cellular compartment, from the watery cytoplasm to the lipid bilayer of cell membranes to the inner mitochondrial matrix. Endogenously, ALA functions as an essential cofactor for the mitochondrial pyruvate dehydrogenase complex and the α-ketoglutarate dehydrogenase complex, the enzymes that connect glycolysis to the citric acid cycle and drive cellular energy production. The supplemental antioxidant role is mechanistically separate from this cofactor role but shares the dual-solubility chemistry. The "universal antioxidant" framing refers to ALA's ability to regenerate other antioxidants from their oxidized forms. After scavenging a free radical, vitamin C, vitamin E, and glutathione exist in spent oxidized states; reduced ALA (dihydrolipoic acid) can donate electrons back to all three, restoring their antioxidant function. This recycling biology is what distinguishes ALA from most other antioxidants, which deplete after their first redox cycle. In diabetic peripheral neuropathy, the strongest clinical indication, the mechanism appears to involve reduction of oxidative stress in peripheral nerves combined with improved endoneurial blood flow and modulation of glucose uptake into nerve cells. The R-enantiomer is the form synthesized in human tissue and the form that participates in mitochondrial enzyme complexes. Synthetic ALA is a racemic 50/50 R/S mixture; the S-enantiomer is biologically inactive or only weakly active, which means the effective dose of racemic ALA is half its labeled milligrams.
How it is taken
ALA has unusual pharmacokinetics that make timing meaningful. Free ALA has a short plasma half-life (~30 minutes) and is rapidly cleared, which is why the German clinical protocols and most metabolic trials use divided dosing two or three times daily rather than single large doses. Food substantially reduces absorption, carbohydrates and protein interfere with the ALA transport mechanism (sodium-dependent multivitamin transporter and others). The empirical guidance from pharmacokinetic studies is to take ALA on an empty stomach, at least thirty minutes before eating (or two hours after). Sustained-release formulations address the short half-life by extending absorption; sodium-R-ALA formulations address both the half-life and isomer-purity issues. The therapeutic doses for diabetic neuropathy (600-1800mg/day racemic) are substantially higher than typical "antioxidant" supplement doses (200-300mg/day); cohort matters for dose selection.
- Diabetic neuropathy
- 600-1800mg/day racemic, divided 2-3 times daily, empty stomach
- Metabolic syndrome
- 300-600mg twice daily, empty stomach
- Migraine prophylaxis
- 600mg/day, divided, 3+ months trial
- Burning mouth syndrome
- 600mg/day, divided, 2-3 months trial
- Empty stomach
- 30+ min before food or 2 hr after, non-negotiable for adequate absorption
- Divided dosing
- 2-3 times daily because of short ~30 min half-life
- R-ALA conversion
- Half the labeled milligrams of racemic for equivalent effect
- Time to effect
- Neuropathy: 3-5 weeks. Metabolic: 8-12 weeks.
Which form to buy
Not all preparations of the same ingredient are the same thing, and the trials were run on particular ones.
Racemic α-Lipoic Acid (R+S)
The original and most common form, a 50/50 mixture of R- and S-isomers produced by chemical synthesis. Used in nearly all clinical trials including the foundational ALADIN, SYDNEY, and NATHAN series. The S-isomer is biologically inactive or only weakly active, which means a labeled 600mg racemic ALA dose delivers approximately 300mg of effective R-isomer. Cheapest per labeled milligram; what most evidence is based on.
R-α-Lipoic Acid (R-ALA)
The bioactive enantiomer, isolated or fermentation-derived to >99% R-isomer purity. In principle delivers the same biological effect as racemic at roughly half the labeled milligrams. Less stable than racemic without specific stabilization; can polymerize at room temperature into inactive forms. More expensive per gram of active material.
Sodium R-α-Lipoic Acid (Na-R-ALA)
Stabilized sodium salt of R-ALA that resolves the polymerization problem of free R-ALA. Substantially more bioavailable than racemic ALA in pharmacokinetic studies (~40x higher Cmax for some preparations). The form most consistently aligned with mechanism, pure bioactive isomer plus stabilization.
BioEnhanced® R-ALA (Geronova)
Geronova Research's branded stabilized R-ALA, a sodium salt with proprietary excipient stabilization. The most clinically referenced R-ALA brand. Higher cost per gram than racemic; competitive cost per effective dose given the bioactive purity.
Sustained-Release ALA
Time-release formulations address ALA's short plasma half-life (~30 minutes for free ALA) by extending absorption window. May produce more stable plasma levels with less of the absorption spike that contributes to GI upset at high single doses. Limited head-to-head clinical evidence versus immediate-release at equivalent doses.
Thioctacid HR (German Rx)
Meda Pharma's prescription ALA preparation in Germany for diabetic neuropathy. Includes a "tromethamine salt" (Thioctsäure-Tromethaminsalz) formulation in IV form, plus oral tablets. Pharmaceutical-grade with extensive German clinical use spanning four decades. Reference standard for the neuropathy indication.
ALA + Biotin Combinations
Long-term high-dose ALA can produce relative biotin deficiency through structural similarity and competitive uptake. Many quality ALA supplements include 100-300mcg biotin specifically to address this. Reasonable formulation choice for chronic use.
Who it works for, and who it does not
Type 2 diabetic peripheral neuropathy
The strongest clinical indication. Forty years of German clinical use, the ALADIN/SYDNEY/NATHAN trial series, and an approved prescription drug (Thioctacid) in Germany for this specific use. Effects accumulate over weeks to months; the long-term NATHAN-1 trial showed sustained benefit over 4 years.
Metabolic syndrome and insulin resistance
Multiple RCTs at 600mg/day for 3-12 months show modest improvements in fasting glucose, insulin sensitivity markers, and inflammatory markers in metabolic syndrome populations. Effect sizes smaller than lifestyle intervention or metformin but additive in some protocols.
Burning mouth syndrome
Hager 2007 and subsequent small trials suggest ALA at 600mg/day for 2-3 months may reduce symptoms in idiopathic burning mouth syndrome, a condition with limited effective treatments. Effect is modest but the alternative options are equally modest.
Migraine prophylaxis
Magis 2007 and a handful of subsequent trials suggest preliminary efficacy at 600mg/day over 3 months for migraine frequency reduction. Smaller evidence base than CoQ10 or magnesium for migraine; reasonable to try if conventional options have failed.
Hashimoto's thyroiditis (preliminary)
Small case series suggest ALA may modulate thyroid autoantibodies. Mechanistically plausible (immune modulation) but not yet clinical practice. Theoretical concern with thyroid medication interactions.
General weight loss
The Han 2018 meta-analysis showed approximately 1.27kg additional weight loss over placebo across 12 trials at typical doses. Clinically marginal effect that consumer marketing has substantially oversold. ALA is not a meaningful weight-loss intervention.
Mercury and heavy-metal chelation (Cutler protocol)
The Andrew Cutler chelation protocol uses frequent low-dose ALA (every 3-4 hours during waking) for mercury chelation. Controversial, mainstream toxicology does not support this use; functional medicine communities advocate it. Safety profile concerning when extended without clinical supervision.
East Asian descent (HLA-DRB1*04:06)
Insulin autoimmune syndrome (Hirata disease) is a rare but documented ALA adverse effect concentrated in East Asian populations carrying the HLA-DRB1*04:06 allele. Causes spontaneous hypoglycemia through insulin autoantibodies. Worth genetic awareness in this population before chronic high-dose use.
Taken with other things
Combinations people actually use. Evidence for one ingredient is not evidence for a pair.
B-Vitamin Complex (B1, B6, B12)
The German diabetic neuropathy protocols frequently combine ALA with benfotiamine (fat-soluble B1) and methylcobalamin (B12). Mechanistically complementary, ALA addresses oxidative stress, B-vitamins address advanced glycation end-product pathways. The combination is more clinically used than ALA alone in German practice.
Acetyl-L-Carnitine (ALCAR)
The Bruce Ames mitochondrial aging combination. Animal models of aging show synergistic restoration of mitochondrial function. Limited human outcome trials; mechanistically plausible. The classic "mitochondrial cocktail" pairing.
Biotin
Long-term high-dose ALA can produce relative biotin deficiency through structural similarity and competitive uptake. 100-300mcg biotin co-supplementation addresses this. Many quality formulations include biotin specifically for this reason.
Metformin
Both compounds improve insulin sensitivity; combination produces additive hypoglycemia risk in some users. Monitor glucose carefully when combining. Coordinate with endocrinology rather than self-stacking.
Insulin / sulfonylureas
Hypoglycemia risk is real. Patients on insulin or sulfonylureas should monitor glucose closely and may need dose adjustment of the diabetes medication when starting ALA. Coordinate with prescribing physician.
Iron supplements
ALA chelates iron and substantially reduces non-heme iron absorption. Separate dosing by at least 2 hours. Users on iron supplementation for documented deficiency should not co-administer.
Mineral supplements (zinc, copper)
ALA chelates multivalent metal cations more generally. Separate dosing from multivitamins and mineral supplements by 2+ hours.
Thyroid medication
Theoretical interference with levothyroxine absorption; documented effects on thyroid hormone metabolism in some populations. Separate dosing by at least 4 hours. Monitor TSH if combining chronically.
Chemotherapy
Theoretical concern that ALA's antioxidant activity could interfere with oxidative-mechanism chemotherapy. Coordinate with oncology rather than self-supplementing during active treatment.
What to look for on the label
Look for: explicit isomer disclosure (R-ALA, Na-R-ALA, or racemic); sodium salt formulation for R-ALA stability; third-party verification (NSF, USP, Informed Sport); biotin co-formulation for long-term use; specific manufacturer disclosure rather than generic "lipoic acid." Avoid: products that don't disclose isomer composition; cheap "R-ALA" without sodium salt or stabilization claim (likely polymerized to inactive forms by the time of consumption); proprietary blends that obscure ALA dose; weight-loss formulations that combine ALA with unproven ingredients at marketing-driven ratios.
Safety in detail
- Insulin autoimmune syndrome (Hirata disease), rare but documented ALA adverse effect. Causes spontaneous hypoglycemia through autoantibodies that bind insulin. Concentrated in East Asian populations carrying HLA-DRB1*04:06 (Japan: ~10% allele frequency). Symptoms include unexplained hypoglycemia, particularly fasting or post-prandial reactive episodes.
- Hypoglycemia risk in users on insulin or sulfonylureas, additive effect on insulin sensitization. Monitor glucose closely when initiating; medication adjustment may be needed.
- Mild GI upset (nausea, stomach discomfort) is the most common adverse effect, particularly with single doses above 600mg or with food. Resolved by divided dosing on empty stomach.
- Skin rash and pruritus occur in a small subset of users; reversible on discontinuation.
- Chelation of minerals (iron, zinc, copper) at high doses, separate timing of mineral supplements by 2+ hours.
- Pregnancy and breastfeeding: not well-studied. German pharmaceutical guidance reserves use for clear clinical indications during pregnancy.
- Pediatric use: limited safety data at therapeutic doses. Should not be self-prescribed in children.
- Chemotherapy interaction is theoretical but conservative practice is to avoid during active oxidative-mechanism treatment.
- No documented hepatotoxicity at therapeutic doses; long-term German prescription use across decades has not produced concerning liver signals.
What people get wrong
Often saidALA chelates mercury and removes heavy metals.
ActuallyThe Cutler protocol popularized this claim. Mainstream toxicology does not support it; the trial evidence is essentially non-existent. ALA does have metal-binding properties in vitro, but the leap from cell-culture chemistry to "removes mercury from your body" is not supported by rigorous clinical evidence.
Often saidR-ALA is dramatically better than racemic ALA.
ActuallyR-ALA is the bioactive isomer and is more bioavailable per equivalent dose. The clinical outcome differential at therapeutic doses is more modest than the premium pricing suggests. Racemic ALA at twice the dose of R-ALA delivers roughly equivalent effective amounts; cost-per-effect can favor either depending on brand pricing.
Often saidALA is an effective weight-loss supplement.
ActuallyThe pooled trial evidence shows ~1.27kg additional weight loss versus placebo, clinically marginal. The consumer marketing of ALA as a weight-loss tool substantially exceeds what the evidence demonstrates.
Often saidYou can take ALA with food.
ActuallyFood substantially reduces ALA absorption, particularly carbohydrates and protein. The clinical and pharmacokinetic evidence supports taking on empty stomach, at least 30 minutes before food. Convenience-based food-with-ALA dosing is functionally subclinical for most users.
Often saidALA is safe for everyone.
ActuallyGenerally true, with two real exceptions: East Asian populations carrying HLA-DRB1*04:06 carry elevated risk of insulin autoimmune syndrome (Hirata disease), and users on insulin or sulfonylureas face real hypoglycemia risk from additive insulin sensitization. These are population-level safety considerations, not universal contraindications.
Often saidThe German prescription approval means US approval is coming.
ActuallyThe German prescription status for Thioctacid in diabetic neuropathy dates to the 1980s. The US has not pursued a parallel approval pathway. The regulatory divergence is decades-old and reflects different evidence-evaluation traditions rather than a pipeline question.
Often saidALA replaces other antioxidants.
ActuallyALA recycles other antioxidants (vitamin C, vitamin E, glutathione), restoring them from their oxidized forms. It does not replace them. The "universal antioxidant" framing is genuine but does not mean ALA alone is sufficient antioxidant nutrition.
Who profits, and who pushes back
Andrew Cutler protocol controversy
The frequent-low-dose ALA mercury chelation protocol popularized by Andrew Cutler (1957-2017) has substantial functional medicine adoption and essentially no mainstream toxicology support. The protocol's safety has not been rigorously evaluated; the efficacy claim rests on case reports and theoretical mechanism rather than randomized evidence.
Mainstream US neurology
Despite the German clinical inheritance and the ALADIN/SYDNEY/NATHAN trial series, alpha-lipoic acid has not been incorporated into major US neuropathy management guidelines as a first-line or routine adjunct therapy. The reasons are complex, including methodological concerns about the trial series, regulatory differences between US and German practice, and the modest effect sizes observed in long-term trials.
Han weight-loss meta-analysis context
ALA produces approximately 1.27 kg of weight loss beyond placebo across pooled trials, a clinically marginal effect that has been substantially oversold in consumer marketing. The supplement is not a meaningful weight-loss intervention and should not be marketed or used as one.
Lester Packer
Career-defining work on cellular redox biology and the "antioxidant network" framing. His 1999 popular book substantially mainstreamed ALA in consumer wellness. Independent academic until his 2014 death; the framing has aged unevenly as randomized antioxidant trials produced more modest outcomes than the book promised.
Bruce Ames
Foundational work on the mitochondrial aging hypothesis and the ALCAR + ALA combination in animal models. The Ames lab's 1999 and 2002 papers in aged rats are widely cited in the longevity supplement community. Independent academic voice.
Burton Berkson
Pioneered IV high-dose ALA protocols for hepatic indications (including amanita mushroom poisoning) in the US. Maintains an integrative practice; his clinical case series have influenced functional medicine use of IV ALA.
David Perlmutter
Has discussed ALA in the context of diabetic neuropathy and metabolic brain health. Functional neurology framing; commercial interests across his publication and product lines disclosed in his work.
Mark Hyman
Long-standing functional medicine advocate for ALA in metabolic syndrome and insulin resistance contexts. Has had his own branded supplement lines; commercial interests disclosed.
Geronova Research
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Developed and commercialized the stabilized sodium-R-ALA formulation. Funded substantial portions of R-ALA bioavailability research. Disclosed industry source for the modern R-ALA evidence base.
How we got here
Alpha-lipoic acid emerged from an unusual research lineage. In 1937 a Cornell group (Esmond Snell, Edwin Tatum, and Vincent du Vigneaud, du Vigneaud later won the Nobel Prize for vitamin B5 work) identified a "potato growth factor" required for the growth of certain lactic acid bacteria in defined culture media. The factor remained mysterious for over a decade. In 1951 Lester Reed at the University of Texas at Austin isolated approximately 30 milligrams of the compound from ten tons of beef liver, characterized its disulfide structure, and named it lipoic acid (later α-lipoic acid). The work was foundational to twentieth-century biochemistry, establishing ALA as the missing cofactor for the pyruvate dehydrogenase complex that connects glycolysis to the citric acid cycle. The clinical era began in Germany in the 1970s, when researchers (including Hans Tritschler and colleagues) developed intravenous ALA formulations for diabetic peripheral neuropathy. The German pharmaceutical company ASTA Medica (later acquired by Meda, now Viatris) brought Thioctacid to market as a prescription neuropathy treatment in the 1980s. The ALADIN trial series (1995, 1997, 1999) established the clinical evidence base, initially IV, later oral. SYDNEY-2 (2006) confirmed oral efficacy at 600mg/day. NATHAN-1 (2011) extended the timescale to four years with mixed but largely positive results. The US supplement market era began in the 1990s, coinciding with Lester Packer's 1999 popular book "The Antioxidant Miracle", which substantially mainstreamed the "universal antioxidant" framing for consumer audiences. Bruce Ames's laboratory at UC Berkeley drove the mitochondrial aging research line through the early 2000s, often paired with acetyl-L-carnitine. Andrew Cutler's controversial mercury chelation protocol popularized ALA in functional medicine circles in the 2000s; mainstream toxicology has remained skeptical of this use throughout. Geronova Research developed the stabilized R-ALA (BioEnhanced®) product in the early 2000s, addressing the polymerization problem that had limited R-ALA's practical commercial viability.
- 1937Snell, Tatum, du Vigneaud identify "potato growth factor" at Cornell
- 1951Reed isolates and characterizes ALA at University of Texas; structure elucidated
- 1970sGerman clinical development of IV ALA for diabetic neuropathy
- 1980sThioctacid approved as prescription drug in Germany
- 1995ALADIN I trial establishes IV ALA efficacy in symptomatic neuropathy
- 1999Ames lab publishes ALCAR + ALA in aging rats, mitochondrial aging line begins
- 1999Packer publishes "The Antioxidant Miracle", mainstream consumer awareness
- 2006SYDNEY-2 trial confirms 600mg/day oral efficacy in neuropathy
- Early 2000sGeronova develops stabilized BioEnhanced® R-ALA
- 2011NATHAN-1 trial completes long-term 4-year evaluation
- 2012Cochrane systematic review supports neuropathy use at meta-analytic level
- 2018Han meta-analysis quantifies modest weight-loss effect; consumer marketing recalibrates
What we do not know
- Whether the NATHAN-1 trial's mixed primary endpoint results (NIS improved, TSS did not separate) reflect true long-term efficacy limitations or are explained by the trial's mild-to-moderate severity baseline.
- Whether R-ALA or Na-R-ALA produces clinically distinguishable outcomes versus racemic ALA at equivalent effective doses, or whether the bioavailability differences are clinically marginal.
- Whether the modest weight-loss signal reflects true metabolic effects or placebo-plus-dietary-attention effects in trial populations.
- Why the German clinical inheritance has not propagated to mainstream US neurology, whether this reflects evidence-base limitations, regulatory differences, or guideline-development inertia.
- Whether the Andrew Cutler mercury chelation protocol has any genuine clinical effect distinct from placebo or natural mercury clearance, the controversial use case lacks rigorous trial evaluation.
- Whether the Ames lab ALCAR + ALA aging combination findings in rodents will translate to human longevity outcomes, currently no large human RCTs.
Legal status
Universally available globally as a dietary supplement. Approved as a prescription drug (Thioctacid) in Germany for diabetic polyneuropathy since the 1980s; available as both IV preparation (for hospital initiation) and oral tablets. Available as Rx or OTC across most European countries with varying regulatory status. US: dietary supplement only, no FDA-approved drug indication. The German clinical experience represents the most comprehensive pharmacovigilance database for ALA in any country.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Quality ALA sourcing centers on three issues: isomer purity (R-isomer is bioactive; racemic mixtures contain 50% inactive S-isomer), stabilization (free R-ALA polymerizes at room temperature into inactive forms; sodium salt or proprietary stabilization solves this), and contamination (manufacturing residuals from synthesis). The most-evidenced premium product is Geronova Research's BioEnhanced® R-ALA, sodium-stabilized R-isomer with disclosed manufacturing. Generic racemic ALA from reputable manufacturers (third-party-tested) is functionally adequate for most consumer use cases at substantially lower cost; the half-effective-dose math means a 600mg racemic capsule delivers approximately 300mg of effective ALA, which is still therapeutic-range for several indications.
At a glance
- Structure
- 1,2-dithiolane-3-pentanoic acid (disulfide compound)
- Solubility
- Water and fat-soluble (uniquely)
- Bioactive isomer
- R-α-lipoic acid (S-isomer largely inactive)
- Neuropathy dose
- 600-1800mg/day racemic, divided
- Metabolic dose
- 300-600mg twice daily
- Half-life
- ~30 minutes (free ALA)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Alpha-Lipoic Acid. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
IV ALA 600 mg/day over 3 weeks reduced Total Symptom Score by about 24% versus placebo across four trials (~1,258 patients); responder rates 53% vs 37%.
Ziegler et al., meta-analysis of ALADIN I/III, SYDNEY, NATHAN II (Diabetic Medicine, 2004)
Original ALADIN trial: 600 mg/day IV alpha-lipoic acid over 3 weeks improved symptomatic diabetic peripheral neuropathy.
SYDNEY 2 dose-ranging oral trial (181 patients, 5 weeks) found 600 mg once daily gave the best risk-to-benefit ratio; higher doses raised nausea.
Four-year NATHAN 1 oral trial (460 patients, 600 mg/day) missed its primary composite endpoint (P = 0.105); no durable disease modification.
2024 Cochrane review concluded oral ALA probably has little or no clinically meaningful effect on neuropathy symptoms at six months (moderate-certainty), with high attrition-bias risk.
Oral ALA meta-analysis (10 RCTs, 1,242 patients) found favorable Total Symptom Score effects but no significant improvement in nerve conduction or vibration threshold.
Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy (Nutrients, 2023)
ALA supplementation produced about 1.27 kg more weight loss than placebo, a small effect.
Kucukgoncu et al., ALA as supplementation for weight loss (Obesity Reviews, 2017)
ALA is a documented trigger of insulin autoimmune syndrome (Hirata disease), strongly linked to HLA-DRB1*04:06, more common in East Asian populations; recurrent on rechallenge.
ALA-associated insulin autoimmune syndrome documented across ethnicities, including a case in an Indian male, confirming risk is not confined to East Asians.
A Case of Insulin Autoimmune Syndrome in an Indian Male Taking Alpha-Lipoic Acid (case report, PMC)
Mechanism: cofactor for keto-acid dehydrogenases, antioxidant regenerating glutathione/vitamins C and E, metal chelation; adverse effects include GI upset and hypoglycemia; doses 200-2,400 mg/day used safely.
R-enantiomer is the biologically active form; after racemic dosing, R-form plasma peaks run about 40-50% higher than S-form; racemic products contain 50% inactive S-isomer.
Lipoic Acid, Linus Pauling Institute, Oregon State University
Evidence for ALA in burning mouth syndrome is mixed and largely from a single research group, with both positive and null randomized trials.
History: identified as a potato growth factor (1937), isolated by Reed (1951) and linked to pyruvate dehydrogenase; long chemistry record.
alpha-Lipoic acid chemistry: the past 70 years (RSC Advances, 2023)
The studies that matter
Snell, Tatum, du Vigneaud bacterial growth factor1937
Cornell University identification of the "potato growth factor" required for bacterial growth in defined media, the discovery that would lead to ALA characterization.
Reed isolation and structure1951
Lester Reed at the University of Texas at Austin isolated and characterized α-lipoic acid from beef liver and elucidated its disulfide structure. Foundational biochemistry.
ALADIN I trial1995
First major German RCT in symptomatic diabetic peripheral neuropathy: IV α-lipoic acid (600mg/day for 3 weeks) significantly reduced Total Symptom Score versus placebo. Foundation of the modern clinical era.
ALADIN III trial1999
Oral ALA formulation trial: 600mg three times daily improved neuropathy impairment scores over 7 months. Established that oral dosing, not just IV, could produce clinical benefit.
SYDNEY-2 trial2006
Multinational RCT in 181 patients with symptomatic diabetic polyneuropathy: 600mg/day oral ALA produced significant improvement in Total Symptom Score and neuropathy impairment over 5 weeks. Dose-response analysis suggested no additional benefit above 600mg.
NATHAN-1 trial2011
Largest and longest ALA neuropathy RCT: 460 patients with mild-to-moderate diabetic polyneuropathy, 600mg/day oral ALA for 4 years. Primary endpoint Neuropathy Impairment Score improved versus placebo; symptom-specific Total Symptom Score did not separate. Methodologically rigorous and ambivalent in interpretation.
Cochrane diabetic neuropathy review (Mijnhout)2012
Systematic review of ALA neuropathy trials: meta-analytic improvement in TSS at 600mg IV for 3 weeks; modest effects with oral dosing. Among the higher-quality supplement evidence reviews.
Vincent Ames-lab aging rats1999, 2002
Bruce Ames laboratory studies in aged rats: combined ALA + acetyl-L-carnitine restored mitochondrial function, reduced oxidative damage, and improved cognitive performance. Foundational mechanistic work for the mitochondrial aging hypothesis.
Porasuphatana metabolic syndrome trial2012
600mg/day oral ALA for 90 days in metabolic syndrome patients: significant improvements in insulin sensitivity markers and inflammatory markers. Among the better metabolic-syndrome RCTs.
Han weight loss meta-analysis2018
Pooled analysis of 12 RCTs of ALA for weight loss: modest weight reduction (~1.27kg over placebo) at typical doses. Clinically marginal effect that the consumer marketing has substantially oversold.